Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

3.

Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.

Harris BN, West DS, Johnson J, Hong SH, Stowe CD.

J Manag Care Pharm. 2004 Sep-Oct;10(5):449-55. Erratum in: J Manag Care Pharm. 2005 Jan-Feb;11(1):87.

5.

Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.

Klepser DG, Huether JR, Handke LJ, Williams CE.

J Manag Care Pharm. 2007 Nov-Dec;13(9):765-77.

6.
7.
9.
10.
11.
12.
13.

A practice-based approach for converting from proton pump inhibitors to less costly therapy.

Lucas LM, Gerrity MS, Anderson T.

Eff Clin Pract. 2001 Nov-Dec;4(6):263-70.

PMID:
11769299
14.

Plan-sponsor savings and member experience with point-of-service prescription step therapy.

Motheral BR, Henderson R, Cox ER.

Am J Manag Care. 2004 Jul;10(7 Pt 1):457-64.

15.

Factors associated with choice of pharmacy setting among DoD health care beneficiaries aged 65 years or older.

Linton A, Garber M, Fagan NK, Peterson M.

J Manag Care Pharm. 2007 Oct;13(8):677-86.

16.
17.
18.

Pharmacy benefit spending on oral chemotherapy drugs.

Curtiss FR.

J Manag Care Pharm. 2006 Sep;12(7):570-7.

19.

A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.

Schneeweiss S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avorn J.

Clin Pharmacol Ther. 2006 Apr;79(4):379-88.

PMID:
16580906
20.

Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids.

Meissner BL, Moore WM, Shinogle JA, Reeder CE, Little JM.

J Manag Care Pharm. 2004 May-Jun;10(3):226-33.

Supplemental Content

Support Center